Study Shows Experimental Amgen Bone-Loss Drug Aids Prostate Cancer Patients
California-based Amgen announced Monday that its experimental drug denosumab reduced risks of osteoporosis and vertebral fractures in men being treated with prostate cancer medicines that can cause bone loss.